Rare diseases develop complex problems in healthcare systems. The world’s 7,000-8,000 rare diseases collectively affect more than 300 million people globally although each disease affects less than 1 in 2000 people. Research shows genetic disorders comprise 80% of rare diseases while these conditions remain active throughout an individual’s lifetime. Rare disease patients who are children face a concerning reality because statistics show fifty percent of affected children do not live past their fifth birthday.
These diseases which exist individually in low prevalence rates collectively generate a substantial worldwide healthcare issue. The United States has roughly thirty million people suffering from rare diseases and European numbers show 36 million cases. The total number of rare diseases demonstrates they are not infrequent when analyzed in unison.
The rare disease domain experiences fast changes because of progress in genomic medicine. The growing knowledge of genetics leads to the breakdown of general disease categories into multiple distinct subtypes which are defined through genetic markers. The growing practice of “precision phenotyping” leads to the identification of additional rare disease categories thus requiring better diagnostic and therapeutic solutions.
Healthcare providers along with patients encounter numerous obstacles which challenge their work:
1. Diagnostic Odyssey: Patients with rare diseases experience a 7.6-year wait for diagnosis which requires multiple tests and physician visits. Patients experience worsening health while their families endure both life deterioration and intense frustration because of the prolonged healthcare system journey. During their search for diagnosis patients must consult between 5 to 7 specialists before finally obtaining their correct diagnosis after 2 to 3 misdiagnoses. Patients face delayed treatment and experience heavy emotional and financial strain because of this lengthy diagnostic process.
2. Treatment Limitations: Rare diseases represent 95% of conditions without official FDA-approved treatment options. The high costs of rare disease treatments result from spreading their development expenses across small patient populations. Patients often face a devastating situation when available treatments remain unreachable due to financial constraints or geographic limitations.
3. Economic Considerations: As with all drugs, developing rare disease pharmaceuticals requires considerable investment. The limited number of patients available to recoup expenses produces high treatment prices which generates conflicts between patient access and both payer limitations and pharmaceutical business sustainability. Treatment expenses for orphan drugs can reach above $300,000 per patient annually and some single-treatment costs surpass $2 million. Healthcare systems across the globe face substantial difficulties because of these high costs which forces them to confront difficult choices regarding resource distribution and fairness.
4. Clinical Trial Challenges: The search for sufficient patients in clinical trials proves challenging which leads to both delayed therapy development and increased expenses. Rare disease clinical trials require new approaches such as adaptive trial designs and n-of-1 trials with surrogate endpoints because traditional methods prove ineffective. The spread of patients across different locations makes trial participation demanding because it often necessitates significant travel for participants.
The AI Revolution in Rare Disease Management
The healthcare spectrum for rare disease management receives a complete transformation from artificial intelligence which enables it to diagnose and treat patients and provide ongoing care. Here’s how:
1. Accelerating Drug Discovery and Development
AI transforms the first steps of creating treatments for rare diseases:
Data Processing: The average researcher consumes about 270 scientific papers annually, but AI systems can scan all 50 million yearly publications in minutes to find disease-relevant information. Rare disease research benefits greatly from this capability because important information about these conditions exists across multiple publications and datasets. Through its analysis AI detects relationships between data points which human researchers cannot identify by performing traditional literature assessments.
AI algorithms review intricate genetic data to recognize drug targets for treating rare diseases. The analysis of gene expression patterns with protein interactions and metabolic pathways through AI enables researchers to detect therapeutic targets which might be overlooked otherwise. The systems perform predictive analyses of genetic variations that impact drug responses to allow customized treatment methods.
AI demonstrates exceptional ability in discovering existing medications that could work for rare diseases. AI systems use molecular structure analysis along with mechanism of action data and real-world evidence to identify drug repurposing opportunities that minimize market costs and time needed to develop new treatments. Traditional drug development economics become more manageable through this approach when applied to rare diseases.
Computer simulations provide a means to test drug toxicity without involving animals or human subjects which might decrease both trial duration and expenses. Through these models, researchers can replicate rare disease mutations’ effects on cells and predict therapy outcomes for these defects. Research scientists can create virtual replicas of disease processes known as “digital twins” to evaluate thousands of compounds before conducting expensive in vitro or in vivo tests.
The analysis of patient cells through AI when compared against research data and healthy samples enables faster and more precise medical treatments. Artificial intelligence system evaluates mutations in genetic rare diseases while generating customized treatment recommendations based on individual genetic characteristics.
2. Transforming Patient Identification
AI demonstrates its most transformative potential through patient identification where conventional approaches have demonstrated persistent weaknesses:
Through facial recognition technology, AI systems identify potential patients with genetic conditions by analyzing pictures from social media platforms and other online sources. AI demonstrates excellent accuracy in detecting the subtle facial features which characterize genetic conditions such as Cornelia de Lange syndrome and Williams syndrome and Noonan syndrome. These systems review multiple facial points then match them to established genetic disorder patterns.
AI systems can process electronic health records along with claims data to recognize signs that suggest rare disease patients before official diagnosis occurs. AI algorithms use symptom combinations alongside laboratory test results and prescribed medications and healthcare patterns to create flags for patients who present rare disease indications. The systems develop enhanced capabilities through time by using confirmed diagnosis information to enhance their predictive strength. Medical systems employing this technology identify rare disease patients earlier than traditional diagnostic procedures by approximately 5 years.
Unstructured physician notes containing essential patient symptoms along with observations that hint at rare diseases remain undetected by standard coding systems. AI systems use natural language processing to review clinical notes and extract relevant information which enables the detection of subtle hints that traditional coding systems would overlook.
The recruitment of clinical trial participants becomes more efficient through AI by using precise patient matching against trial requirements. These systems perform constant EHR data screening to detect newly eligible patients which results in significant cost reductions for recruitment efforts. AI technology allows researchers to detect geographical distribution patterns of potential trial participants which leads to better placement of trial sites.
3. Expediting Diagnosis
The diagnostic delay represents the essential barrier AI systems tackle in rare disease management.
The identification of rare disease indicators depends on AI systems that detect subtle patterns between patient symptoms and laboratory test results as well as medical images. These systems demonstrate superior abilities to find combinations of unrelated symptoms which indicate rare medical conditions. Through the analysis of thousands of data points simultaneously, AI detects patterns beyond human recognition for conditions doctors have not previously encountered.
In this work, we first explored the application of machine learning to detect biomarkers of genetic conditions more effectively than traditional methods. In radiological studies, pathology slides, or retinal scans, advanced image analysis can detect subtle abnormalities that could indicate rare diseases. Examples of AI systems that detect rare retinal disorders from standard ophthalmic imaging more accurately than human specialists are available.
• To help physicians diagnose patients faster, AI can assist with differential diagnosis by analyzing patient data more extensively. These systems can rapidly compare a patient’s profile against thousands of rare disease signatures and select conditions that best match the evidence available. AI, when integrated into clinical decision support systems, can provide physicians with probability-ranked differential diagnoses as well as suggested confirmatory tests to assist in the diagnostic process.
• Genetic variant interpretation can be greatly aided using AI which can analyze the vast amounts of genetic data produced by next generation sequencing. Pathogenic variants can be identified in complex datasets by AI algorithms that also predict their clinical significance. AI can help geneticists distinguish disease-causing mutations from benign variants by integrating multiple data sources including population databases, functional studies, and clinical records, which accelerates the diagnosis of genetic rare diseases.
• The most important feature of AI diagnostic systems is that they learn and improve with time as they analyze more cases.
4. Enhancing Market Access and Treatment Adoption
The business side of rare disease treatment is also being improved by AI, which is addressing the substantial commercial challenges that have traditionally restricted investment in this space:
• Machine learning can assist in establishing pricing models that optimize patient results, payer worth and manufacturer financial stability. AI can quantify the true value of rare disease therapies by analyzing real-world evidence of treatment effectiveness, patient quality of life improvements and healthcare utilization changes. This knowledge facilitates more elaborate value-based contracts between manufacturers and payers, which can alleviate the conflict between the high costs of therapies and the limited resources available for reimbursement.
• Analysis of submission dossiers with the aid of AI can determine the factors that influence time to reimbursement and thus potentially save millions of dollars in lost revenue from delayed market access. AI can determine which evidence elements, structural features and presentation approaches are most likely to result in favourable and rapid regulatory decisions by examining historical submission data. This optimization can make a big difference to the overall commercial success of rare disease therapies because for these diseases every day of market exclusivity counts.
• Patient Journey Mapping: AI can gather data from various sources to create an entire patient path for certain rare diseases and pinpoint at which points new treatments would be most valuable. Pharmaceutical companies can develop better targeted value propositions and educational materials for patients and healthcare providers through this insight.
• AI can produce highly accurate budget impact models through the integration of demographic data, disease prevalence information, treatment patterns, and cost data. Tools that analyze the financial effects of rare disease therapies on payers and assist manufacturers in determining prices for sustainability and access are provided by these tools.
• For rare disease therapies, selecting the right physicians is crucial but challenging. The identification of rare disease patients by physicians can be determined through the analysis of prescription patterns, referral networks, diagnostic coding, and other data sources by AI. Educational outreach and marketing efforts can be made more efficient through this approach, thus reducing the time between product launch and patient benefit.
Eularis AI in Rare Disease Identification: A Case Study
Eularis has been a pioneer in developing new ways to identify rare disease patients for almost 20 years, and this is where AI makes a big difference:
Case Study 1: Facial Recognition for Early Patient Identification
The Client Problem:
• A pharmaceutical company developed a medication for an extremely rare disease.
• It was crucial to locate patients early since the condition advances with time and patients would die before adulthood if not found.
• There was a low probability that most doctors would diagnose these patients as there were so few that most physicians would never see one in their lifetime.
The AI Solution:
• Identifying that certain facial traits were common in children with the condition
• Facial recognition software was developed for detecting potential patients
• Utilizing algorithms to examine online photos from social media sites such as Facebook and Flickr
• Through the use of targeted advertisement to the people who had uploaded photos of children detected with the condition, they were sent to a disease information website.
The Process:
1. Algorithms would go through parental posts of diagnosed patients that mentioned symptoms related to the condition to identify language searched on by known parents.
2. AI created to detect children who had facial features characteristic of the rare disease from photos uploaded online
3. When parents (who had uploaded a photo in which we had detected had the condition) looked for information online on the symptoms their child exhibited, advertisements related to these symptoms would appear.
4. These ads pointed parents to disease awareness website about the condition.
5. Through this information, parents would then be able to present themselves to physicians and this would help in faster diagnosis.
The Outcome:
Thirteen new patients were identified rapidly. With treatment costs of approximately $500,000 per patient per year for life, the ROI was substantial, but more importantly, these patients received life-saving treatment that might otherwise have been delayed or missed entirely. This project was done over 20 years ago and the approaches we use today vary from those initial early successes and are even more powerful today.
Case Study 2: Accelerating Clinical Trial Recruitment
The Client Problem:
• A Phase II clinical trial for a specific rare cancer type had recruited only 2 patients
• The trial was behind schedule
The AI Solution:
• Big data (EHR and claims) with AI analysis to:
• Identify patients with a high probability of having that specific rare cancer for the trial.
• Due to the removal of identifying information for the patients and physicians in the EHR data we triangulated the EHR data with Claims data and were about to identify the physicians
o Visualizations of the physicians with potential patient locations were created
o Select clinical trial sites
o Physicians with suspected patients were contacted for patient checking
o Confirmed patients were recruited
The Outcome:
Within just a short time of system completion, an additional 6,472 eligible patients were identified, dramatically accelerating the clinical trial process. Not anywhere near that was required for the PII trial so they then had enough patients for their PIII trial as well.
Future Directions and Considerations
As AI continues to evolve, several promising directions are emerging:
1. Decentralized Clinical Trials: AI is enabling fully remote clinical trials that eliminate geographic barriers to participation. Wearable devices, telehealth platforms, and AI-powered monitoring systems enable researchers to conduct trials for rare disease patients in any location. These approaches not only accelerate recruitment but also generate more comprehensive real-world data that better reflects patient experiences outside clinical settings.
2. Digital Biomarkers: AI is helping identify novel digital biomarkers for rare diseases through analysis of data from smartphones, wearables, and home monitoring devices. These digital signatures can track disease progression, treatment response, and quality of life with unprecedented granularity. In cases where traditional biomarkers are absent, digital alternatives may offer essential outcome measures for both clinical practice and research.
3. Federated Learning Systems: Algorithms in federated learning can be trained on data from multiple institutions while protecting sensitive patient information from being shared. This approach is particularly valuable for rare diseases, where relevant data is often scattered across numerous specialized centres. The implementation of federated learning for collaborative AI development is likely to accelerate rare disease research because it allows for the development of AI while upholding privacy and regulatory compliance.
4. Integration Across Healthcare Systems: Standardization of AI tools will enable healthcare providers to share patient information and coordinate care better. Achieving the full potential of AI in rare disease management requires interoperable AI systems that can function with diverse EHR platforms, imaging systems, and laboratory databases.
5. Ethical Considerations: Use of facial recognition and other identification tools is a concern when it comes to privacy which needs to be addressed properly. When we conducted the life-saving rare disease patient diagnosis tool many years ago the regulations for this did not exist as they do now. Even though the potential gains for patients are great, there must now be proper consent procedures in place, data management protocols that are easily understandable, and an assessment of the potential negative consequences. For paediatric populations, ethical frameworks need to capture the balance between the need to diagnose conditions quickly and the need to protect privacy and autonomy.
6. Collaborative Approaches: It is important that technology companies, pharmaceutical developers, patient advocacy groups and healthcare providers work together to harness the impact of AI. There is no one organization that has all the knowledge, data and resources required to tackle rare diseases in full. Unprecedented collaboration across traditional boundaries, with patient voices and experiences at the centre of these efforts will be required for successful AI implementation.
7. Regulatory Evolution: The regulatory systems for artificial intelligence in healthcare remain in development especially when it comes to new applications such as patient identification and diagnostic support. Developers need to work closely with regulatory authorities to develop approaches which promote both safety and innovation. Flexible regulatory pathways that recognize the distinct obstacles of rare disease research will become essential because of the high level of urgent need in this field.
Conclusion
The implementation of artificial intelligence systems drives major changes in rare disease management through faster drug development as well as improved diagnostic capabilities and patient identification systems. The millions of rare disease patients receive new hope through artificial intelligence which enables earlier medical detection and more effective treatments and better health results. Traditional diagnostic odysseys that produce years of uncertainty and suffering together with progressive damage might disappear into history.
The pharmaceutical industry will gain substantial advantages through AI because clinical trials will operate more efficiently and receive faster regulatory approval which leads to better investment returns. Artificial intelligence transforms the economic models of rare disease drug development thus making possible new investment opportunities for previously ignored conditions.
AI-powered rare disease management will provide major advantages to healthcare systems. The costs of misdiagnosis and inappropriate interventions and disease progression decrease when patients receive earlier diagnosis and effective treatment. AI enables the improvement of rare disease care delivery to address both patient-specific requirements and organizational resource limitations.
The ongoing technological progress will expand AI capabilities for rare disease management which may lead to complete treatment availability for all rare diseases. The examples provided by Eularis and other leading organizations prove that this potential future has already started taking shape in the present day. The rare disease community consisting of patients and their families along with clinicians and researchers and industry partners can transform the rare disease experience of millions worldwide through AI technology which offers more than incremental change.
Found this article interesting?
Dr Bates posts regularly about AI in Pharma so if you follow her you will get even more insights.
2. Listen to our AI for Pharma Growth Podcast
Revolutionize your team’s AI solution vendor choice process and unlock unparalleled efficiency and save millions on poor AI vendor choices that are not meeting your needs! Stop wasting precious time sifting through countless vendors and gain instant access to a curated list of top-tier companies, expertly vetted by leading pharma AI experts.
Every year, we rigorously interview thousands of AI companies that tackle pharma challenges head-on. Our comprehensive evaluations cover whether the solution delivers what is needed, their client results, their AI sophistication, cost-benefit ratio, demos, and more. We provide an exclusive, dynamic database, updated weekly, brimming with the best AI vendors for every business unit and challenge. Plus, our cutting-edge AI technology makes searching it by business unit, challenge, vendors or demo videos and information a breeze.
- Discover vendors delivering out-of-the-box AI solutions tailored to your needs.
- Identify the best of the best effortlessly.
- Anticipate results with confidence.
Transform your AI strategy with our expertly curated vendors that walk the talk, and stay ahead in the fast-paced world of pharma AI!
Get on the wait list to access this today. Click here.
4. Take our FREE AI for Pharma Assessment
When we analysed the most successful AI in biopharma and their agencies, we found there are very specific strategies that deliver the most consistent results year after year. This assessment is designed to give clarity as to how to achieve a successful outcome from AI.
The first step is to complete this short questionnaire, it will give us the information to assess which process is right for you as a next step.
It’s free and obligation-free, so go ahead and complete it now. Plus receive a free link to our a free AI tools pdf and our 5 day training (30 mins a day) in AI in pharma. Link to assessment here.
5. Learn more about AI in Pharma in your own time
We have created an in-depth on-demand training about AI specifically for pharma that translate it into easy understanding of AI and how to apply it in all the different pharma business units — Click here to find out more.